Breast Cancer


  • ALLIANCE Z11102– Phase II Study of Impact of Breast-Conserving Surgery and Radiotherapy in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
  • ECOG E1Z11- A Cohort Study to Evaluate Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Women with Stage I-III Breast Cancer
  • ALLIANCE A01114– Study reviewing the effect of Preoperative Breast MRI on Surgical Outcomes, Costs, and Quality of Life of Women with Breast Cancer
  • WFU 98213– Preventing Antracycline Cardiovascular Toxicity with Statins (PREVENT)
  • URCC 14079– Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis


  • RTOG 0631– A Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis
  • NSABP B-51- A Phase III Randomized Clinical Trial Evaluating Standard or Comprehensive Radiation Therapy in Treating Patients with Early Stage Breast Cancer Previously Treated with Chemotherapy and Surgery


  • CALGB 40903– A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma In Situ (DCIS)
  • ECOG-ACRIN E4112– Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)

Triple Negative

  • ECOG EA1131- A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy.
  • NRG BR-003– A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positve or High Risk Node-Negative Triple-Negative Invasive Breast Cancer.

HER2 Negative BRCA Mutations

  • NSABP B-55– A Randomized Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

HER2 Positive

  • NSABP B-52- A Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor Positive, Her-2 Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Estrogen Deprivation (temporarily closed to accrual)

ER and/or PR Positive/HER2 Negative

  • SWOG S1207A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer
  • ECOG E2112– A Phase III Randomized Clinical Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor -Positive that is locally Advanced or Metastatic Breast Cancer
  • Alliance A011106– Alternate Approaches for Clinical Stage II and III Estrogen Receptor Positive Breast Cancer NeoAdjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study


Positive Sentinel Lymph Node

  • Alliance A011202– A Randomized Phase II Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy


  • ECOG E2108 – A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
  • SWOG S1222– A Randomized Phase III Trial of Fulvestrant alone versus Fulvestrant and Everolimus versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients with Hormone-Receptor-Positive Stage IV Breast Cancer (Temporarily closed)
  • NRG-BR002– A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
  • Alliance A011203– A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer.